1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 1: Summary of patient characteristics in systematic review and case series of temporal bone Schneiderian neoplasms^{^a}
Characteristic 
Demographics (n = 76) 
 Age at presentation (median) (IQR) 53 (44–63)
 Sex ratio (male/female) 1.5 (45:31)
Main presenting otologic signs/symptoms (n = 76)^{^b} 
 Hearing loss 51 (67%)
 Otorrhea or otorrhagia 36 (47%)
 Aural fullness 14 (18%)
 Otalgia 13 (17%)
 Tinnitus or pulsatile tinnitus 12 (16%)
 Acute or chronic otitis media and/or mastoiditis 9 (12%)
 Visible ear mass 9 (12%)
 Facial paralysis 7 (9%)
 Dizziness or vertigo 2 (3%)
Association of temporal bone tumor with sinonasal tumor (n = 76) 
 Primary (isolated) 37 (49%)
 Secondary 39 (51%)
Temporal association of secondary tumor diagnosis with sinonasal tumor (n = 39) 
 Synchronous 9 (23%)
 Metachronous 30 (77%)
Temporal bone tumor pathology (n = 74) 
 Benign 48 (65%)
 Malignant 26 (35%)
Sinonasal tumor pathology (n = 39) 
 Benign 24 (62%)
 Malignant/high-risk 15 (38%)
↵a Missing data are excluded from the denominators of each section.
↵b Cells add up to >100% as cases may feature multiple presenting signs/symptoms.